Artyx Pharmaceuticals Inc is categorized under Research Services in San Diego, CA and active since 2003.
Artyx Pharmaceuticals Inc was established in 2003, and today employs 1 to 4, earning $100.000 to $499.999 per year. This is a Research Services business, which does work in the B2B market, and is classified as a Research Services, under code number 541910 by the NAICS.
If you are seeking more information, feel free to contact Waldemar Lernhardt Phd at the company’s single location by writing to 9025 Balboa Avenue # 110, San Diego, California CA 92123 or by phoning No number given. You can also visit this business on Facebook by going to their profile page at Facebook or on find them on Twitter.
| Business Name: | Artyx Pharmaceuticals Inc |
| Contact Person: | Waldemar Lernhardt Phd |
| Address: | 9025 Balboa Avenue # 110, San Diego, California 92123 |
| Website Address: | artyxpharma.com |
| Annual Revenue (USD): | $100.000 to $499.999 |
| Founded: | 2003 |
| Location Type: | Single Location |
| Employee Number: | 1 to 4 |
| Business Type: | B2B (Business to Business) |
| Business Category: | Research Services |
| SIC Code: | 8732 |
| NAICS Code: | 541910 |
| Share This Business: |
Artyx Pharmaceuticals Inc was started in 2003 to provide professional Research Services under the SIC code 8732 and NAICS code 541910. Since its inception, the company has gone on to take a total of 1 to 4 personnel under its employment and has achieved earnings of $100.000 to $499.999 per annum.
Feel free to contact Waldemar Lernhardt Phd for inquiries that concern Artyx Pharmaceuticals Inc by calling the company number No number given, as your correspondence is most welcome. Additionally, the physical location of the single location of Artyx Pharmaceuticals Inc can be found at the coordinates 32.822063,-117.133093 as well as the street address 9025 Balboa Avenue # 110 in San Diego, California 92123.
For its online presence, you may visit Artyx Pharmaceuticals Inc’s website at artyxpharma.com and engage with its social media outlets through on Twitter and on Facebook.